www.dermscan.com

TOPAZ OY

Study report #21E1365

Related to quote #21D1365

EVALUATION OF THE CUTANEOUS ACCEPTABILITY AND EFFICACY OF A COSMETIC PRODUCT -USE TEST UNDER DERMATOLOGICAL CONTROL -

Teepuusaippua

CLINICAL INVESTIGATION CENTER	
	EUROFINS DERMSCAN POLAND Sp. z o. o. Ul. Matuszewskiego 12 80 - 288 GDANSK POLAND _____ Tel. + 48 58 732 02 90

Study coordination:
EUROFINS Dermscan/Pharmascan Project Manager
Ms Anna CZERMAŃSKA: acz@dermscan.pl
Project Manager Assistant
Ms Karina GURBIN: kgu@dermscan.pl

Investigator
Ms Ewa KARAMON (dermatologist)

Document 1/1 including 47 pages

TABLE OF CONTENTS

KEY ELEMENTS OF THE STUDY #21E1365

EVALUATION OF THE CUTANEOUS ACCEPTABILITY AND EFFICACY OF A COSMETIC PRODUCT - USE TEST UNDER DERMATOLOGICAL CONTROL -

Claim

- Tolerance tested under dermatological control.

Objectives

To evaluate for the studied product:

- its ability to maintain human body in good condition (cutaneous acceptability) proven by clinical examination by the dermatologist;
- its efficacy to reduce imperfections/blemishes by counting retentional and inflammatory lesions by the dermatologist;
- subjectively its cosmetic acceptability, efficacy and future use by analysis of the subjects' answers to a subjective evaluation questionnaire;
- potential adverse events collection.

Methodology

- Open, intra-individual study; each subject is his/her own control;
- Before / After.

Kinetics

	Evaluation zone	D0	D0-D27	D28 (±1)
Information of the subject about study conditions and collection of his/her informed consent.	Face	●		
Verification of inclusion and non-inclusion criteria.		●		
Clinical examination by the dermatologist assess the cutaneous state of the face.		●		●
Counting of the retentional and inflammatory lesions by the dermatologist.		●		●
Distribution (d) / collection (c) of the daily log.		● (d)		● (c)
Product application by the subjects at home.			●	
Subjective evaluation questionnaire.				●
Potential adverse event collection.				●

Foreseen dates

Product reception	Study start	Study end	1st results by e-mail
June 8th, 2021	January 21st, 2022	April 1st, 2022	April 26th, 2022

Product

Reference	Form	Application zone
Teepuusaippua	Bar of soap	Face

Study Population

Specific inclusion criteria

- **Sex:** female and/or male;
- **Age:** 18-40 years old;
- **Phototype:** I to IV;
- Subjects presenting a skin prone to acne on the face (with at least 10 retentional and 5 inflammatory lesions).

Number of subjects analyzed	Average age
22	23(±1) years (between 18 and 40)

1 QUALITY CONTROL STATEMENT

The person responsible for the final quality control certifies that the study above was conducted as closely as possible to Good Clinical Practice (GCP-ICH), in compliance with the study protocol and EUROFINS Dermscan/Pharmascan standard operating procedures and that the study report reflects raw data.

QUALITY CONTROL ASSESSOR	
Last name	SIEKLUCKA
First name	Anna
Date	06/07/2022
Signature	Sieklucka

Conclusion

Under these study conditions, after 28 days of once or twice daily use, we observed that:

Product "Teepuusaippua"

ANTI-ACNE EFFECT

Statistically significant decrease was observed in the number of blackheads and microcysts (global retentional lesions) as well as in the number of papules and pustules (global inflammatory elements).
Therefore, in global lesions was observed a statistically significant decrease.

→ **ANTI-ACNE EFFECT**

CUTANEOUS ACCEPTABILITY

11 subjects (#6, 7, 8, 9, 11, 12, 15, 17, 19, 20 and 22) reported functional signs and six of them (#6, 7, 17, 19, 20 and 22) reported also physical signs. Moreover three subjects (#4, 13 and 14) reported only physical signs. Signs reported by 2 subjects (#7 and 13) were judged as relevant. Two clinical signs (#17 and 20) (worsened in comparison to D0 state) was observed on D28. One of them (#17) was judged as relevant.
Under these study conditions, after 28 days of once or twice daily use the Investigator judged the product "Teepuusaippua" as well-tolerated on the cutaneous level.

→ **WELL-TOLERATED ON THE CUTANEOUS LEVEL**

QUESTIONNAIRE

Good subjective appreciation after 28 days of use

100% of the subjects find that the product is easy to use and did not notice any unusual appearance of spots and/or blackheads;
95% of the subjects find that the product is easy to rinse;
87% of the subjects find that the product foams well;
86% of the subjects find that the product is pleasant to use and the skin is purified;
82% of the subjects would like to continue to use the product;
77% of the subjects find that the product reduces pimples and imperfections and that they would buy this product (regardless of the price) at the end of the study;
73% of the subjects find that the skin is soft and product is suitable for their skin type;
Globally 77% of the subjects appreciate the product.

→ **APPRECIATED BY THE MAJORITY OF SUBJECTS**

The product can claim
"TOLERANCE TESTED UNDER DERMATOLOGICAL CONTROL"

	Name and job title	Date	Signature
Project Manager Assistant	**Karina GURBIN**	05/07/2022	
Investigator	**Ewa KARAMON (dermatologist)**	12/07/22	

2 STUDY PROCESS

EUROFINS Dermscan/Pharmascan is certified ISO: 9001-2015.

EUROFINS Dermscan/Pharmascan benefits from a governmental Research Tax Credit from the French Ministry of Research.

The study is carried out on a cosmetic product whose safety has been assured by the Sponsor.
Its aim is to further confirm, under normal and reasonably foreseeable use conditions, the capacity of a product to maintain human body in good condition.

The European Directive 2001/20/EC and regulations issued by the Minister of Health (Order of the Minister of Health of May 2, 2012 regarding Good Clinical Practice, Dz.U. 2012, item 491) is not applicable. Therefore, this study is considered as non-interventional and does not require the Ethics Committee Approval and the Competent Authority Authorization.

+ See ethical requirements and regulatory standards in **Appendix 8.**

This study was conducted under the following conditions:

2.1 POPULATION

2.1.1 Selection

INCLUSION CRITERIA
Specific
• **Sex:** female and/or male; • **Age:** 18-40 years old; • **Phototype:** I to IV; • Subject presenting a skin prone to acne on the face (with at least 10 retentional and 5 inflammatory lesions).
General
• Healthy subject; • Subject having given his/her free informed, written consent; • Subject willing to adhere to the protocol and study procedures.

NON-INCLUSION CRITERIA
• For women: pregnant or nursing woman or woman planning to get pregnant during the study; • Cutaneous pathology on the study zone (eczema, etc.); • Use of topical or systemic treatment during the previous weeks liable to interfere with the assessment of the cutaneous acceptability of the study product; • Subject with make-up on the day of the visit at the laboratory; • Subject having undergone a surgery under general anesthesia within the previous month; • Excessive exposure to sunlight or UV-rays within the previous month; • Subject enrolled in another clinical trial during the study period (concerns the studied zones); • Subject who was abroad in a country with a higher incidence rate of Covid-19 than Poland, within 14 days before the beginning of the study; • Subject presenting following symptoms: cough, shortness of breath, elevated body temperature - equal and above 37.5°C; • Subject who had contact with any person infected with COVID-19 within 10 days before the beginning of the study; • Subject who is currently during home quarantine recommended by the Sanitary Inspection.

2.1.2 Study requirements and constraints

DURING THE STUDY, THE SUBJECTS		
HAVE TO	**MUST NOT**	**ARE ALLOWED TO USE*** (except on visiting days)
• respect dates and hours of evaluation visits; • complete the daily-log and bring it back at the end of the study; • avoid excessive UV exposure (including artificial UV); • wear protective mask (does not concern face skin evaluations) and disinfect hands during the visits at the laboratory.	• apply any product to test areas the days of the visits* to the investigation center; • apply any other similar product (face cleansers) to test areas during the study; • modify their usual hygiene or care products and/or use new products; • allow the use of the study product by another person than herself/himself.	• usual face care products (without anti-acne properties); • usual make-up and make-up removal products.

** a wash with the usual or tested product is allowed before the visit to the investigation center.*

2.1.3 Compliance assessment

The compliance is controlled by checking the daily log.

+ See **Appendix 7.2**.

2.1.4 Protocol deviations

A protocol deviation can be defined as any non-adherence to the final protocol, including:

- wrong inclusion (inclusion criteria or non-inclusion criteria not fulfilled);
- start of a prohibited concomitant treatment;
- non-adherence of the subjects to the study schedule (missed or postponed visit);
- missing data for one or several evaluation criteria;
- low compliance of the subject to the study product(s) application;
- premature study end or untraceable subject;
- no respect of the constraints envisaged by the protocol.

Deviations to the protocol should be classified as:

- **minor** if they don't impact the rights, safety or well-being of the subjects. They do not increase the risk for the subject and/or do not have a significant effect on the integrity of the data collected,
- **major (or protocol violations**) if they affect the rights, safety or well-being of participants. They increase the risk for the subject and/or have a significant effect on the integrity of the study data,
- **critical:** any protocol violations as mentioned above necessarily requiring the suspension or the termination of the study.

In case of minor protocol deviation, the technician or the investigator repeats the instructions and reminds the subject to follow protocol requirements / study procedures. In case of persistent or major protocol violations, the subject is declared non-compliant and withdrawn from the study because of non-compliance.

The non-adherences observed are presented in the following table:

Subject#	Description of the non-adherence	Type of non-adherence (minor / major)	Data kept in the analysis (yes/no)
5	The subject returned on D31 instead of D28.	minor	yes
	The subject did not use the product in the morning before the visit on D31.	minor	yes
6	The subject returned on D31 instead of D28.	minor	yes
7	The subject returned on D31 instead of D28.	minor	yes
21	The subject returned on D32 instead of D28.	minor	yes

- The protocol non-adherence of the subjects #5, 6, 7 and 21 did not invalidate the data obtained for these subjects.

2.1.5 Concomitant treatments

- **None of the concomitant medications started after the beginning of the study invalidated the data obtained for any subject.**
  + See the concomitant medications table in **Appendix 7.3.**

2.1.6 Follow-up

	Number of SUBJECTS				
	INCLUDED	COMPLETING THE STUDY	ANALYZED	NOT COMPLETING THE STUDY	NOT ANALYZED
Cutaneous acceptability/ Anti-acne effect / Subjective evaluation	22	22	22	/	

2.1.7 Demographic data

ANALYZED SUBJECTS (included in at least one analysis)	SEX	AGE (IN YEARS)			Face skin type	Sensitive skin on the face	COMMENTS AND DETAILED DATA
		Mean ± SEM	Min.	Max.			
22	Female: 13 Male: 9	23±1	18	40	Combination: 15 Greasy: 7	Yes: 19 No: 3	See **Appendix 7.1**





2.2 INVESTIGATIONAL PRODUCT

2.2.1 Description

Reference	Batch#	Form	Packaging	Confidentiality procedure	Storage temperature
Teepuusaippua	4491	Bar of soap	25 x 105g	Encoded	Room temperature

2.2.2 Application

Zone	Frequency	Directions for use
Face	Once or twice a day	Wet the skin and apply the soap gently with a sponge. Rinse well. Use your usual moisturizer if needed.

2.2.3 Labelling

Example of labelling of each product by EUROFINS Dermscan/Pharmascan and translation:

DERMSCAN Badanie n°	DERMSCAN Study #
Nr Ochotnika: ..... Nr Dermscan: ..... W nagłej potrzebie:	Subject#:..... Dermscan ref.:..... Emergency telephone number: .....
Warunki przechowywania:	Conservation: .....
Przechowywać z dala od dzieci i ich zasięgu wzrokowego. Stosować pod kontrolą medyczną tylko dla potrzeb badania.	Keep out of reach and sight of children. To be used only under strict medical supervision for clinical trial.

2.2.4 Storage

Until the beginning of the study, products are kept at room temperature in a dedicated air-conditioned room, which is locked and access controlled.

2.2.5 Attribution to the subjects

➔ *Product*

All the subjects receive the same product reference.

➔ *Application zones*

Not applicable. All the subjects apply the product to the same zone.

2.2.6 Handing-out

The products are delivered to the subjects by the investigator with an explanation of the application conditions.

2.2.7 Future

As far as possible, one sample of the study product is kept by the investigation center for a period of six months after its receipt.

- **By default, the products (used and not used) are destroyed at the end of the study according to the current internal EUROFINS Dermscan/Pharmascan procedures.**

2.3 STUDY STAGES

ON D0:

Subjects:
- come to the investigation center without having applied any product on the face since the previous evening (except the morning wash with usual product);
- are informed about the trial objectives, the procedures and the risks of the study with the information sheet;
- sign two copies of the Consent Form.

Dermatologist:
- conducts an epidemiological interview;
- verifies inclusion and non-inclusion criteria;
- performs a clinical examination of the skin on the face;
- asks the subjects about their usual unpleasant sensations (cutaneous level);
- counts the elements (blackheads, microcysts, papules and pustules) on the whole face (except nasal pyramid);
- gives to the subjects:
  - the **product** to be used according to the instructions in 2.2.1 and 2.2.2,
  - the **daily log** to write down their possible unpleasant sensations or medications.

  + See **Appendix 7.2**.

ON D28 (±1) (last application being done in the morning on the day of the visit – D28):

Subjects:
- return to the investigation center without having applied any product to the studied zone since the previous evening (except the morning wash with tested product);
- bring back their daily log and study product/packaging;
- fill in the subjective evaluation questionnaire.

  + See **Appendix 7.6**.

Dermatologist:
- conducts an epidemiological interview;

- performs a new clinical examination of the skin on the face;
- asks the subjects about the unpleasant sensations they felt during the study to assess the cutaneous acceptability of the study product;
- counts the lesions (blackheads, microcysts, papules and pustules) on the whole face (except nasal pyramid).

2.4 DATA ANALYSIS

The following data are analyzed:

	Parameter(s)	Unit(s)	Variation(s) DX/D0 Kinetics	Statistical analysis (tick if yes)	Expected result(s)
Cutaneous acceptability	Clinical signs observed Functional and physical signs reported by the subjects	/	D28/D0	/	No worsening
Anti-acne effect	Number of retentional lesions (blackheads and microcysts) and inflammatory elements (papules and pustules)	/	D28/D0	X	↘
Subjective evaluation	Questionnaire	%	D28	Majority of positive answers	

Individual data are presented in raw value tables. These tables also show the descriptive statistics: means, medians, minima, maxima, standard errors of the means (SEM) and confidence intervals of 95% (95% CI).

2.4.1 Calculation formulas

The variations (Δ) and in percentage on the mean (Δ%) are calculated according to the following formulas:

$$\Delta = TZ_{ti} - TZ_{t0}$$

with: TZ: value obtained on the zone treated by the tested product
t0: before product application
ti: at each measurement time after product application

2.4.2 Statistical method



Analysis conditions	p-value	H0	Conclusion
Type I error (α) = 5% in bilateral / unilateral mode	**p ≤ 0.05**	Rejected	Statistically significant difference
Null hypothesis (H0)= no difference between means(1) or medians(2)	**p > 0.05**	Not rejected	No statistically significant difference

2.4.3 Statistical software

The software used is Excel and SAS 9.4.

2.5 AUDIT AND TRIAL MONITORING VISIT

An audit and/or trial monitoring visit may be carried out at the Sponsor's request or by the appropriate regulatory authority. The aim of the monitoring visit is to verify that the study is conducted according to the determined protocol and current regulations.

- **No monitoring visit occurred for this study.**

3 PRINCIPLES AND RESULTS

3.1 UNDESIRABLE EFFECTS / ADVERSE EVENTS

No Undesirable Effects was observed during the study.

No Serious Adverse Event was reported during the study.

3.2 CUTANEOUS ACCEPTABILITY

3.2.1 Principle

Before (D0) and after 28 days of the product use, the subject's face is examined by the dermatologist in charge of study to assess each of the following parameters:

	NONE	VERY MILD	MILD	MODERATE	SEVERE
Erythema	☐	☐	☐	☐	☐
Edema	☐	☐	☐	☐	☐
Dryness	☐	☐	☐	☐	☐
Desquamation	☐	☐	☐	☐	☐
Roughness	☐	☐	☐	☐	☐
Others	☐	☐	☐	☐	☐
Please define:	.....				

On D0, the subjects are also asked about their usual functional and physical signs (usual ones and felt on D0):

	NONE	VERY MILD	MILD	MODERATE	SEVERE
Tightness	☐	☐	☐	☐	☐
Stinging	☐	☐	☐	☐	☐
Itching	☐	☐	☐	☐	☐
Warm, burning sensation	☐	☐	☐	☐	☐
Redness/ Erythema	☐	☐	☐	☐	☐
Edema	☐	☐	☐	☐	☐
Dryness	☐	☐	☐	☐	☐
Desquamation	☐	☐	☐	☐	☐
Roughness	☐	☐	☐	☐	☐
Others	☐	☐	☐	☐	☐
Please define:	.....				

At the end of the study, the cutaneous acceptability of the product is assessed by taking into account the relevant elements reported by the subject (functional and physical signs) as well as those noted during the examination (clinical signs).
The confrontation of these signs is used to conclude on the final cutaneous acceptability of the studied product.



3.2.2 Summary of the results

❖ *Clinical signs*



Observed clinical signs		
SUBJECT NUMBER	TYPE OF SIGNS	RELEVANCE
17	**Mild dryness around the lips and on the cheeks on D28 (likely imputable). Mild desquamation around the lips and on the cheeks on D28 (likely imputable). Mild roughness around the lips and on the cheeks on D28 (likely imputable).**	**Relevant**
20	Mild discoloration on the side of the face on D28 (unlikely imputable).	Not relevant

❖ *Functional and physical signs reported by subjects*



Functional & physical signs reported by the subjects			
SUBJECT NUMBER	FUNCTIONAL SIGNS	PHYSICAL SIGNS	RELEVANCE
4	None	Mild redness on the forehead and under the eyes area two minutes after product application during 20 minutes on D0 (likely imputable, usual sign). Very mild redness under the eyes two minutes after the product application during ten minutes on D1 (likely imputable, usual sign). Very mild redness under the eyes three minutes after the product application during 10 minutes on D2 (likely imputable, usual sign). Very mild redness on the nose and under the eyes one minute after the product application during 20 minutes on D3 (likely imputable, usual sign). Very mild redness on the nose one minute after the product application during up to 30 minutes from D4 to D9 (likely imputable, usual sign).	Not relevant
6	Very mild tightness on the whole face one minute after the product application during ten minutes on D0 (likely imputable, usual sign). Mild burning sensation pointwise on the pustules just after the product application during 15 minutes on D12 (likely imputable).	Mild dryness on the whole face just after the product application during all day on D4 (likely imputable).	Not relevant
7	**Moderate itching on the whole face just after the product application during less than five minutes from D6 to D9 (likely imputable). Mild tightness on the whole face just after the product application during less than five minutes from D14 to D28 (likely imputable, usual sign).**	**Moderate dryness on the whole face just after the product application during less than five minutes from D3 to D13 (likely imputable). Mild dryness on the whole face just after the product application during less than five minutes from D14 to D30 (likely imputable, usual sign).**	**Relevant**
8	Mild burning sensation on the cheeks two minutes after the product application during eight minutes on D1 (likely imputable, usual sign).	None	Not relevant
9	Very mild tightness around the eyes ten minutes after the product application during less than five minutes on D0 and D1 (likely imputable).	None	Not relevant
11	Mild tightness on the cheeks two minutes after the product application during less than five minutes on D3 (likely imputable).	None	Not relevant
12	Very mild tightness on the cheeks and forehead one minute after the product application during five minutes from D0 to D2 (likely imputable, usual sign). Very mild itching on the cheeks and forehead one minute after the product application during five minutes on D0 (likely imputable). Very mild tightness on the forehead just after the product application during five minutes from D3 to D8 (likely imputable, usual sign).	None	Not relevant

Functional & physical signs reported by the subjects			
SUBJECT NUMBER	FUNCTIONAL SIGNS	PHYSICAL SIGNS	RELEVANCE
13	**None**	**Moderate dryness around the nose five minutes after the product application during all day on D0 (likely imputable). Mild dryness around the nose area five minutes after the product application during all day on D1 (likely imputable). Mild dryness on the cheeks five minutes after the product application during all day from D2 to D5 (likely imputable). Mild dryness on the cheeks just after the product application during all day from D14 to D19 and from D21 to D23 (likely imputable). Moderate dryness on the cheeks just after the product application during all day on D20 (likely imputable). Very mild dryness on the cheeks just after the product application during all day from D24 to D28 (likely imputable).**	**Relevant**
14	None	Mild dryness on the cheeks just after the product application during less than five minutes on D2, D3 and D5 (likely imputable). Mild redness on the cheeks just after the product application during less than five minutes on D2, D3 and D5 (likely imputable, usual sign). Moderate dryness on the cheeks just after the product application during less than five minutes on D4 (likely imputable). Moderate redness on the cheeks just after the product application during less than five minutes on D4 (likely imputable, usual sign). Very mild dryness on the cheeks just after the product application during less than five minutes on D6, D7, D26 and D27 (likely imputable, usual sign). Very mild redness on the cheeks just after the product application during less than five minutes on D6, D7, D17, D26 and D27 (likely imputable, usual sign).	Not relevant
15	Mild tightness on the cheeks just after the product application during less than five minutes from D0 to D13 (likely imputable, usual sign). Very mild tightness on the cheeks just after the product application during less than five minutes from D14 to D28 (likely imputable, usual sign). Very mild tightness on the forehead just after the product application during less than five minutes on D14 and D24 (likely imputable, usual sign).	None	Not relevant
17	Mild itching on the cheeks five minutes after the product application during 20 minutes from D0 to D2 (likely imputable, usual sign). Mild tightness on the cheeks five minutes after product application during 20 minutes on D2 (likely imputable). Mild tightness on the whole face five minutes after the product application during ten minutes from D3 to D6 (likely imputable). Mild itching on the whole face five minutes after the product application during ten minutes on D3 (likely imputable, usual sign). Very mild tightness on the whole face five minutes after the product application during five minutes on D7 and D8 (likely imputable, usual sign).	Mild redness on the whole face five minutes after the product application during 20 minutes from D0 to D2 (likely imputable, usual sign). Mild redness on the whole face five minutes after the product application during ten minutes from D3 to D6 (likely imputable, usual sign).	Not relevant
19	Very mild tightness on the cheeks and chin just after the product application during less than five minutes on D5 (likley imputable).	Very mild dryness on the cheeks just after the product application during less than five minutes on D4 (likley imputable).	Not relevant

Functional & physical signs reported by the subjects			
SUBJECT NUMBER	FUNCTIONAL SIGNS	PHYSICAL SIGNS	RELEVANCE
20	Mild burning sensation on the cheeks and forehead two minutes after the product application during 20 minutes on D0 (likely imputable, usual sign). Mild tightness on the cheeks and forehead two minutes after the product application during 20 minutes on D0 (likely imputable, usual sign). Mild burning sensation on the cheeks and chin just after the product application during two hours on D17 and D18 (likely imputable, usual sign). Mild itching on the cheeks and chin just after the product application during two hours on D17 and D18 (likely imputable, usual sign). Severe burning sensation on the chin just after the product application during all the time on D19 (likely imputable). Severe itching on the chin just after the product application during all the time on D19 (likely imputable, usual sign). Severe tightness on the chin just after the product application during all the time on D19 (likely imputable, usual sign). Moderate itching on the chin just after the product application during all the time on D20 (likely imputable, usual sign).	Mild redness on the cheeks and chin just after the product application during two hours on D17 and D18 (likely imputable, usual sign). Mild dryness on the cheeks and chin just after the product application during two hours on D17 and D18 (likely imputable, usual sign). Severe redness on the chin just after the product application during all the time on D19 (likely imputable). Severe dryness on the chin just after the product application during all the time on D19 (likely imputable). Moderate dryness on the chin just after the product application during all the time on D20 (likely imputable, usual sign).	Not relevant
22	Severe burning sensation on the cheeks and forehead just after the product application during all the time from D1 to D4 (likely imputable). Moderate burning sensation on the cheeks and forehead just after the product application during all the time on D5 (likely imputable). Mild burning sensation on the cheeks and forehead just after the product application during all the time on D6 (likely imputable).	Severe dryness on the cheeks and forehead just after the product application during all the time from D1 to D4 (likely imputable). Moderate dryness on the cheeks and forehead just after the product application during all the time on D5 (likely imputable). Mild dryness on the cheeks and forehead just after the product application during all the time on D6 (likely imputable).	Not relevant

11 subjects (#6, 7, 8, 9, 11, 12, 15, 17, 19, 20 and 22) reported functional signs and six of them (#6, 7, 17, 19, 20 and 22) reported also physical signs. Moreover three subjects (#4, 13 and 14) reported only physical signs. Signs reported by 2 subjects (#7 and 13) were judged as relevant. Two clinical signs (#17 and 20) (worsened in comparison to D0 state) was observed on D28. One of them (#17) was judged as relevant.
Under these study conditions, after 28 days of once or twice daily use the Investigator judged the product "Teepuusaippua" as well-tolerated on the cutaneous level.

3.3 ANTI-ACNE EFFECT

3.3.1 Principle

The anti-acne effect is assessed after 28 days of use, in comparison with the number of lesions on the face before application (D0).
On D0 and D28, blackheads and microcysts (retentional lesions) as well as papules and pustules (inflammatory lesions) are counted on the whole face (except nasal pyramid) by the dermatologist.

The variations (D28-D0) in the number of lesions are calculated for each kind of lesions. Descriptive statistics are done in order to determine the variation significance.

ANTI-ACNE EFFECT OF THE PRODUCT

- **Decrease in the number of retentional and inflammatory lesions**

3.3.2 Summary of the results

The individual results are presented in **Appendix 7.5.**
A synthesis of the results obtained is presented below:

Parameter	Kinetics	Variation (mean ±SEM)	Δ%	p	Type of statistical test	Significance	% of subjects presenting improvement
Blackheads	D28	-5 ± 1	-38%	<.0001	Wilcoxon	Yes	77%
Microcysts		-6 ± 1	-79%	<.0001	t-test	Yes	91%
Global retentional lesions		-10 ± 1	-53%	<.0001	t-test	Yes	95%
Papules		-4 ± 1	-58%	<.0001	Wilcoxon	Yes	91%
Pustules		-3 ± 1	-82%	<.0001	t-test	Yes	91%
Global inflammatory lesions		-7 ± 1	-67%	<.0001	t-test	Yes	100%
Global lesions		-17 ± 2	-58%	<.0001	t-test	Yes	100%



After 28 days of once or twice daily use, of the product: "Teepuusaippua":
- a significant decrease was observed in the number of blackheads and microcysts (global retentional lesions) as well as in the number of papules and pustules (global inflammatory elements);
- a significant decrease was observed in the number of **global lesions**.

Under these study conditions, the product "Teepuusaippua" can therefore be considered as having an anti-acne effect.

3.4 SUBJECTIVE EVALUATION QUESTIONNAIRE

3.4.1 Principle

A subjective evaluation questionnaire, submitted by the Sponsor, is filled in by the subjects at the end of the study on D28 to subjectively evaluate the properties, the efficacy and the future use of the studied product.

3.4.2 Summary of the results

The subjects' answers to the subjective evaluation questionnaire are presented in **Appendix 7.6.**

To be easier to read, the percentages are rounded off. The sum of these percentages may be different from 100%.

- **In this study (n=22), one subject represents 4.5%.**

A synthesis of the answers is presented below. In comparison with the theoretical proportion of 50% and population number (n=22), the results > 71.3% are considered as significant according to the calculation of the bilateral confidence interval of a proportion.

AFTER 28 DAYS OF USE	
GENERAL APPRECIATION OF THE PRODUCT AND ITS PROPERTIES	
What is you global appreciation of the product?	**77%**
Very pleasant	32%
Pleasant	45%
Is the use of product easy?	**100%**
Agree	86%
Somewhat agree	14%
Did you find this product pleasant to use?	**86%**
Agree	59%
Somewhat agree	27%
PRODUCT'S EFFICACY	
The skin is soft	**73%**
Agree	9%
Somewhat agree	64%
The skin is healthy looking	68%
Agree	27%
Somewhat agree	41%
The skin is purified	**86%**
Agree	50%
Somewhat agree	36%
The product does not dry out the skin	46%
Agree	14%
Somewhat agree	32%
The product is suitable for dry skin (if applicable) (n=15)	40%
Agree	13%
Somewhat agree	27%
The product is suitable for sensitive skin (if applicable) (n=19)	42%
Agree	16%
Somewhat agree	26%
The product reduces pimples and imperfections	**77%**
Agree	50%
Somewhat agree	27%
The product is easy to rinse	**95%**
Agree	77%
Somewhat agree	18%
The product foams well	**87%**
Agree	64%
Somewhat agree	23%
The product leaves the skin comfortable	64%
Agree	32%
Somewhat agree	32%
The product is suitable for my skin type	**73%**
Agree	32%
Somewhat agree	41%

A synthesis of the answers is presented below. In comparison with the theoretical proportion of 50% and population number (n=22), the results > 71.3% are considered as significant according to the calculation of the bilateral confidence interval of a proportion.

AFTER 28 DAYS OF USE

ACCEPTABILITY	
During this study did you feel any cutaneous irritation sensation? No	32%
During this study did you notice any unusual appearance of spots and/or blackheads? No	**100%**
FUTURE USE OF THE PRODUCT	
Would you like to continue to use the product? Yes	**82%**
At the end of this study would you like to buy this product (regardless of the price)? Yes	**77%**








PRODUCT'S EFFICACY
95%
87%
73%
100%
80%
60%
40%
20%
0%
satisfied subjects %
The product is easy to rinse
The product foams well
The product is suitable for my skin type


ACCEPTABILITY
100%
100%
80%
60%
40%
20%
0%
satisfied subjects %
During this study did you notice any unusual appearance of spots and/or blackheads?


FUTURE USE
82%
77%
100%
80%
60%
40%
20%
0%
satisfied subjects %
Would you like to continue to use the product?
At the end of this study would you like to buy this product (regardless of the price)?

Vol	Q4 What did you LIKE about this product?
1	I felt that my skin was cleansed.
2	Smooth skin after the wash.
3	Product size, it was convienient.
4	The product improved the skin condition while using it reguralry. It was gentle and effective.
5	Product is effective and easy to use.
6	The product is effective. No new breakouts occured after use.
7	None
8	Product is pleasant and easy to apply.
9	Easy to spread and use. Foams well.
10	It is easy to rinse off.
11	The product is effective and easy to use.
12	Fragrance.
13	The product is easy to use. It dried out the greasy skin.
14	Foams well and it is efficient.
15	It is easy to apply.
16	Removes the impurities, cleanses the skin and foams well.
17	It is easy to rinse off.
18	It is effective.
19	Pleasant fragrance.
20	Pleasant fragrance and it is easy to rinse off.
21	Soft skin after product use.
22	It is easy to apply.

Vol	Q5 What did you DISLIKE about this product?
1	None
2	None
3	None
4	Intensive fragrance.
5	None
6	At the beginning of use it dried out the skin.
7	None
8	Fragrance.
9	Fragrance.
10	Intensive fragrance.
11	The product slightly irritated the skin.
12	It did not foam well.
13	When used regularly it dried the skin out too much.
14	Fragrance.
15	Fragrance.
16	The bar product type (liquid would be better).
17	None
18	Fragrance.
19	It dried out hands due to application.
20	Sometimes a mild burning sensation occured.
21	None
22	Mild irritating smell.

4 CONCLUSION

Under these study conditions, after 28 days of once or twice daily use, we observed that:



5 CERTIFICATION

The study is conducted according to Helsinki Declaration (1964) and its successive updates. Data are obtained using the study protocol, current internal procedures and as closely as possible to the guidance on Good Clinical Practice CPMP / ICH / 135 / 95 (R2).

This study is totally performed under the responsibility of EUROFINS Dermscan/Pharmascan.

All the observations and numerical data collected throughout the study are reported in this document and are in accordance with the obtained results.

	INVESTIGATOR - dermatologist	PROJECT MANAGER ASSISTANT
Name	Ewa KARAMON	Karina GURBIN
Date	12/07/2022	05/07/2022
Signature		

Any modifications are the sole responsibility of the author of the modification, whether he/she is acting for the Sponsor or independently.

The on-line publishing, on the Internet, of this study report with the names and signatures is strictly prohibited.

6 BIBLIOGRAPHY

Regulatory

1. ICH TOPIC E6 (R2)/ Note for guidance on Good Clinical Practice- CPMP / ICH / 135 / 95, November 2016.

2. WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI/ Ethical Principles for Medical Research Involving Human Subjects- Helsinki Declaration (1964) and its successive updates.

3. Order of the Minister of Health May 2, 2012 (Dz.U. 2012 poz.491)

4. REGULATION (EU) 2016/679 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation)

5. REGULATION (EC) No 1223/2009 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 30 November 2009 on cosmetic products (recast).

6. Commission Regulation (EU) No 655/2013 of 10 July 2013 laying down common criteria for the justification of claims used in relation to cosmetic products

7. ANSM / IMPUTABILITE DES EFFETS INDESIRABLES LIES AUX PRODUITS COSMETIQUES, 2013. http://ansm.sante.fr/var/ansm_site/storage/original/application/5dbe53023c2f828bdbed348b4a942a91.pdf

Cutaneous acceptability

1. IGIELSKA-KALWAT J, GOŚCIAŃSKA J, WITKOWSKA B, NOWAK I. / In vivo studies of substances used in the cosmetic industry - Advances in Dermatology and Allergology. 2016; 33(3):163-169.

2. SALVERDA et AL. / Results of a cosmetovigilance survey in The Netherlands - Contact Dermatitis. 2013; 68: 139-148.

3. BROECKX W., BLONDEEL A., DOOMS-GOOSSENS A., ACHTEN G. / Cosmetic intolerance - Contact Dermatitis. 1987; 16: 189-194.

4. ROBERT P. and coll. / Dermopharmacologie clinique - EDISEM MALOINE, 1985.

Comedogenic potential

1. BAEK J.H., AHN S.M., CHOI K.M., et al. / Analysis of comedone, sebum and porphyrin on the face and body for comedogenicity assay – *Skin Research and Technology*, 2016, 22: 164-169.

2. KATOULIS A.C., KAKEPIS E.M., KINTZIOU H., et al. / Comedogenicity of cosmetics: a review – *Journal of the European Academy of Dermatology and Venereology,* 1996, 7: 115-119

3. DURUPT G., LEGER E., MONTASTIER / Etude du pouvoir comédogène des produits cosmétiques - *Nouv. Dermatol.,* 1985, 4, 5 : 216-219.

Data analysis

1. SOKAL R. R., ROHLF F. J. / Biometry: the principles and practice of statistics in biological research - 3nd edn.W.H. Freeman and company, New York, 1995.

APPENDICES:

STUDY DOCUMENTS, DETAILED RESULTS
&
ETHICAL REQUIREMENTS AND REGULATORY STANDARDS

7 APPENDICES – STUDY DOCUMENTS/ DETAILED RESULTS

7.1 SUBJECTS' CHARACTERISTICS

Subject #	Last name	First name	Age	Sex	Phototype	Skin type on the face	Skin prone to acne	Retentional lesions at inclusion	Inflammatory lesions at inclusion	Sensitive skin on the face	Comments	D0 date	D28 date	Image reproduction right (Yes / No)
1	SZ	R	19	M	III	G	Yes	30	10	Yes	None	2022-01-21	2022-02-18	Yes
2	HE	S	18	M	II	C	Yes	40	8	Yes	None	2022-01-21	2022-02-18	Yes
3	SI	A	28	F	II	C	Yes	20	15	Yes	None	2022-01-27	2022-02-25	Yes
4	PA	P	21	M	II	C	Yes	20	25	Yes	None	2022-01-31	2022-02-28	Yes
5	WÓ	A	18	M	III	G	Yes	20	10	Yes	Protocol non-adherence	2022-02-01	2022-03-04	Yes
6	SŁ	A	19	M	II	G	Yes	15	10	Yes	Protocol non-adherence	2022-02-01	2022-03-04	Yes
7	HY	K	25	M	III	C	Yes	15	10	Yes	Protocol non-adherence	2022-02-07	2022-03-11	Yes
8	TR	P	24	M	II	C	Yes	15	10	Yes	None	2022-02-08	2022-03-08	Yes
9	BO	P	31	M	II	C	Yes	30	20	No	None	2022-02-08	2022-03-08	Yes
10	WO	S	40	M	II	C	Yes	10	6	Yes	None	2022-02-10	2022-03-10	Yes
11	CZ	W	19	F	II	C	Yes	10	6	Yes	None	2022-02-10	2022-03-10	Yes
12	SZ	A	23	F	II	C	Yes	15	5	Yes	None	2022-02-15	2022-03-15	No
13	BO	W	18	F	II	C	Yes	15	10	Yes	None	2022-02-16	2022-03-16	Yes
14	SI	K	21	F	II	C	Yes	12	5	Yes	None	2022-02-17	2022-03-17	Yes
15	ZA	E	23	F	II	G	Yes	20	10	Yes	None	2022-02-18	2022-03-18	Yes
16	AM	K	32	F	III	C	Yes	25	10	Yes	None	2022-02-18	2022-03-18	Yes
17	WI	E	19	F	II	G	Yes	30	10	Yes	None	2022-02-18	2022-03-18	Yes
18	CH	A	31	F	III	C	Yes	20	10	Yes	None	2022-02-18	2022-03-18	Yes
19	WO	Z	18	F	II	C	Yes	10	10	No	None	2022-03-03	2022-03-31	Yes
20	SŁ	N	18	F	II	G	Yes	20	6	Yes	None	2022-03-03	2022-03-31	Yes
21	HO	M	32	F	II	G	Yes	15	20	No	Protocol non-adherence	2022-03-04	2022-04-05	Yes
22	EW	J	18	F	II	C	Yes	12	6	Yes	None	2022-03-04	2022-04-01	Yes

Mean	23	F	13	I	0	N	0	Yes	22	Mean	19	Mean	11	Yes	19
Median	21	M	9	II	17	D	0	No	0	Median	18	Median	10	No	3
Minimum	*18*			III	5	C	15			*Minimum*	*10*	*Minimum*	*5*		
Maximum	*40*			IV	0	G	7			*Maximum*	*40*	*Maximum*	*25*		
SEM	1									SEM	2	SEM	1		
95% CI	3									95% CI	3	95% CI	2		

Legend: F: female
M: male
N: normal
D: dry
C: combination
G: greasy

7.2 DAILY LOG (TRANSLATION)

eurofins | Dermscan Pharmascan

KARTA BIEŻĄCEJ OBSERWACJI (miejscowo)

PONIŻSZA TABELA MUSI BYĆ WYPEŁNIANA KAŻDEGO DNIA długopisem (nie ołówkiem). Jeśli produkt nie był aplikowany, należy wpisać "0" w polu "Ilość"

Badany produkt

Przypomnienie warunków stosowania produktu

DZIEŃ	DATA	ILOŚĆ DZIENNYCH APLIKACJI	ODCZUWALNY DYSKOMFORT I/LUB OZNAKI NIETOLERAN-CJI	RODZAJ REAKCJI SKÓRNYCH LUB DYSKOMFORTU (np.: zaczerwienienie, obrzęk, suchość, pieczenie, mrowienie, swędzenie, ściąganie ...)	MIEJSCE (np.: policzki, czoło...)	CZAS WYSTĄPIENIA REAKCJI OD MOMENTU APLIKACJI/ZASTOSO-WANIA PRODUKTU (np.: zaraz po aplikacji, po x minutach, itd...)	CZAS TRWANIA (np.: kilka minut, przez cały czas, itd...)	INTENSYW-NOŚĆ 1 bardzo lekkie 2 lekkie 3 średnie 4 ostre	NORMALNY OBJAW PO ZASTOSOWA-NIU TEGO TYPU PRODUKTU (tak lub nie)	UŻYCIE LEKÓW		
										Użycie?	Jaki?, dlaczego?	Jaka dawka? Jak długo?
Np.	*10/12/2020*	1	☒Tak ☐ Nie	*Zaczerwienienie*	*Czoło*	*5 minut po aplikacji*	*10 minut*	*2*	*tak*	☒Tak ☐ Nie	*Paracetamol, ból głowy*	*500 mg x 1*
D0		Rano ☐ Wieczorem ☐	☐ Tak ☐ Nie							☐ Tak ☐ Nie		
D1			☐ Tak ☐ Nie							☐ Tak ☐ Nie		
D2			☐ Tak ☐ Nie							☐ Tak ☐ Nie		
D3			☐ Tak ☐ Nie							☐ Tak ☐ Nie		
D4			☐ Tak ☐ Nie							☐ Tak ☐ Nie		
D5			☐ Tak ☐ Nie							☐ Tak ☐ Nie		
D6			☐ Tak ☐ Nie							☐ Tak ☐ Nie		

..../.....
D28

7.3 CONCOMITANT TREATMENTS

Subject #	Medication (sales name)	Indication	Inclusion date	Start date	End date or "in progress"	Beginning of treatment (compared to the kinetics)	End of treatment (compared to the kinetics)
8	Paracetamol	Fever	2022-02-08	2022-02-28	2022-03-02	D 20	D 22
11	Clatra®	Dog hair allergy	2022-02-10	2022-02-15	2022-02-15	D 5	D 5
			2022-02-10	2022-03-08	2022-03-08	D 26	D 26
13	Paracetamol	Headache	2022-02-16	2022-02-16	2022-02-16	D 0	D 0
		Stomachache	2022-02-16	2022-02-19	2022-02-19	D 3	D 3
14	Paracetamol	Headache	2022-02-17	2022-02-21	2022-02-21	D 4	D 4
	Ibuprom®		2022-02-17	2022-03-13	2022-03-13	D 24	D 24
15	Paracetamol	Headache	2022-02-18	2022-02-21	2022-02-21	D 3	D 3
16	Ibuprom®	Headache and stomachache	2022-02-18	2022-03-02	2022-03-02	D 12	D 12
		Headache	2022-02-18	2022-03-03	2022-03-03	D 13	D 13
			2022-02-18	2022-03-05	2022-03-05	D 15	D 15
	Ibuprom® Sprint		2022-02-18	2022-03-17	2022-03-17	D 27	D 27

7.4 CUTANEOUS ACCEPTABILITY- INDIVIDUAL RESULTS

Cutaneous acceptability

FACE

Subject#	Signs reported by the subjects		Clinical signs observed on D28
	Functional signs	Physical signs	
1	None	None	None
2	None	None	None
3	None	None	None
4	None	Mild redness on the forehead and under the eyes area two minutes after product application during 20 minutes on D0 (likely imputable, usual sign). Very mild redness under the eyes two minutes after the product application during ten minutes on D1 (likely imputable, usual sign). Very mild redness under the eyes three minutes after the product application during 10 minutes on D2 (likely imputable, usual sign). Very mild redness on the nose and under the eyes one minute after the product application during 20 minutes on D3 (likely imputable, usual sign). Very mild redness on the nose one minute after the product application during up to 30 minutes from D4 to D9 (likely imputable, usual sign).	None
5	None	None	None
6	Very mild tightness on the whole face one minute after the product application during ten minutes on D0 (likely imputable, usual sign). Mild burning sensation pointwise on the pustules just after the product application during 15 minutes on D12 (likely imputable).	Mild dryness on the whole face just after the product application during all day on D4 (likely imputable).	None
7	**Moderate itching on the whole face just after the product application during less than five minutes from D6 to D9 (likely imputable).** **Mild tightness on the whole face just after the product application during less than five minutes from D14 to D28 (likely imputable, usual sign).**	**Moderate dryness on the whole face just after the product application during less than five minutes from D3 to D13 (likely imputable).** **Mild dryness on the whole face just after the product application during less than five minutes from D14 to D30 (likely imputable, usual sign).**	None
8	Mild burning sensation on the cheeks two minutes after the product application during eight minutes on D1 (likely imputable, usual sign).	None	None
9	Very mild tightness around the eyes ten minutes after the product application during less than five minutes on D0 and D1 (likely imputable).	None	None
10	None	None	None
11	Mild tightness on the cheeks two minutes after the product application during less than five minutes on D3 (likely imputable).	None	None
12	Very mild tightness on the cheeks and forehead one minute after the product application during five minutes from D0 to D2 (likely imputable, usual sign). Very mild itching on the cheeks and forehead one minute after the product application during five minutes on D0 (likely imputable). Very mild tightness on the forehead just after the product application during five minutes from D3 to D8 (likely imputable, usual sign).	None	None
13	None	**Moderate dryness around the nose five minutes after the product application during all day on D0 (likely imputable).** **Mild dryness around the nose area five minutes after the product application during all day on D1 (likely imputable).** **Mild dryness on the cheeks five minutes after the product application during all day from D2 to D5 (likely imputable).** **Mild dryness on the cheeks just after the product application during all day from D14 to D19 and from D21 to D23 (likely imputable).** **Moderate dryness on the cheeks just after the product application during all day on D20 (likely imputable).** **Very mild dryness on the cheeks just after the product application during all day from D24 to D28 (likely imputable).**	None
14	None	Mild dryness on the cheeks just after the product application during less than five minutes on D2, D3 and D5 (likely imputable). Mild redness on the cheeks just after the product application during less than five minutes on D2, D3 and D5 (likely imputable, usual sign). Moderate dryness on the cheeks just after the product application during less than five minutes on D4 (likely imputable). Moderate redness on the cheeks just after the product application during less than five minutes on D4 (likely imputable, usual sign). Very mild dryness on the cheeks just after the product application during less than five minutes on D6, D7, D26 and D27 (likely imputable, usual sign). Very mild redness on the cheeks just after the product application during less than five minutes on D6, D7, D17, D26 and D27 (likely imputable, usual sign).	None

Cutaneous acceptability

FACE

Subject#	Signs reported by the subjects		Clinical signs observed on D28
	Functional signs	Physical signs	
15	Mild tightness on the cheeks just after the product application during less than five minutes from D0 to D13 (likely imputable, usual sign). Very mild tightness on the cheeks just after the product application during less than five minutes from D14 to D28 (likely imputable, usual sign). Very mild tightness on the forehead just after the product application during less than five minutes on D14 and D24 (likely imputable, usual sign).	None	None
16	None	None	None
17	Mild itching on the cheeks five minutes after the product application during 20 minutes from D0 to D2 (likely imputable, usual sign). Mild tightness on the cheeks five minutes after product application during 20 minutes on D2 (likely imputable). Mild tightness on the whole face five minutes after the product application during ten minutes from D3 to D6 (likely imputable). Mild itching on the whole face five minutes after the product application during ten minutes on D3 (likely imputable, usual sign). Very mild tightness on the whole face five minutes after the product application during five minutes on D7 and D8 (likely imputable, usual sign).	Mild redness on the whole face five minutes after the product application during 20 minutes from D0 to D2 (likely imputable, usual sign). Mild redness on the whole face five minutes after the product application during ten minutes from D3 to D6 (likely imputable, usual sign).	**Mild dryness around the lips and on the cheeks on D28 (likely imputable).** **Mild desquamation around the lips and on the cheeks on D28 (likely imputable).** **Mild roughness around the lips and on the cheeks on D28 (likely imputable).**
18	None	None	None
19	Very mild tightness on the cheeks and chin just after the product application during less than five minutes on D5 (likley imputable).	Very mild dryness on the cheeks just after the product application during less than five minutes on D4 (likley imputable, usual sign).	None
20	Mild burning sensation on the cheeks and forehead two minutes after the product application during 20 minutes on D0 (likely imputable, usual sign). Mild tightness on the cheeks and forehead two minutes after the product application during 20 minutes on D0 (likely imputable, usual sign). Mild burning sensation on the cheeks and chin just after the product application during two hours on D17 and D18 (likely imputable, usual sign). Mild itching on the cheeks and chin just after the product application during two hours on D17 and D18 (likely imputable, usual sign). Severe burning sensation on the chin just after the product application during all the time on D19 (likely imputable). Severe itching on the chin just after the product application during all the time on D19 (likely imputable, usual sign). Severe tightness on the chin just after the product application during all the time on D19 (likely imputable, usual sign). Moderate itching on the chin just after the product application during all the time on D20 (likely imputable, usual sign).	Mild redness on the cheeks and chin just after the product application during two hours on D17 and D18 (likely imputable, usual sign). Mild dryness on the cheeks and chin just after the product application during two hours on D17 and D18 (likely imputable, usual sign). Severe redness on the chin just after the product application during all the time on D19 (likely imputable). Severe dryness on the chin just after the product application during all the time on D19 (likely imputable). Moderate dryness on the chin just after the product application during all the time on D20 (likely imputable, usual sign).	Mild discoloration on the side of the face on D28 (unlikely imputable).
21	None	None	None
22	Severe burning sensation on the cheeks and forehead just after the product application during all the time from D1 to D4 (likely imputable). Moderate burning sensation on the cheeks and forehead just after the product application during all the time on D5 (likely imputable). Mild burning sensation on the cheeks and forehead just after the product application during all the time on D6 (likely imputable).	Severe dryness on the cheeks and forehead just after the product application during all the time from D1 to D4 (likely imputable). Moderate dryness on the cheeks and forehead just after the product application during all the time on D5 (likely imputable). Mild dryness on the cheeks and forehead just after the product application during all the time on D6 (likely imputable).	None

7.5 ANTI-ACNE EFFECT - INDIVIDUAL RESULTS AND STATISTICAL ANALYSIS

7.5.1 Individual results

	Blackheads			Microcysts			Global retentional lesions		
Subject #	D0	D28	ΔD28	D0	D28	ΔD28	D0	D28	ΔD28
1	10.0	10.0	0.0	20.0	3.0	-17.0	30.0	13.0	-17.0
2	30.0	10.0	-20.0	10.0	0.0	-10.0	40.0	10.0	-30.0
3	15.0	10.0	-5.0	5.0	0.0	-5.0	20.0	10.0	-10.0
4	10.0	10.0	0.0	10.0	2.0	-8.0	20.0	12.0	-8.0
5	10.0	2.0	-8.0	10.0	2.0	-8.0	20.0	4.0	-16.0
6	5.0	5.0	0.0	10.0	1.0	-9.0	15.0	6.0	-9.0
7	10.0	8.0	-2.0	5.0	1.0	-4.0	15.0	9.0	-6.0
8	10.0	5.0	-5.0	5.0	1.0	-4.0	15.0	6.0	-9.0
9	15.0	10.0	-5.0	15.0	5.0	-10.0	30.0	15.0	-15.0
10	10.0	8.0	-2.0	0.0	0.0	0.0	10.0	8.0	-2.0
11	8.0	8.0	0.0	2.0	2.0	0.0	10.0	10.0	0.0
12	5.0	5.0	0.0	10.0	3.0	-7.0	15.0	8.0	-7.0
13	10.0	5.0	-5.0	5.0	1.0	-4.0	15.0	6.0	-9.0
14	10.0	5.0	-5.0	2.0	0.0	-2.0	12.0	5.0	-7.0
15	15.0	10.0	-5.0	5.0	3.0	-2.0	20.0	13.0	-7.0
16	15.0	10.0	-5.0	10.0	6.0	-4.0	25.0	16.0	-9.0
17	25.0	10.0	-15.0	5.0	0.0	-5.0	30.0	10.0	-20.0
18	15.0	10.0	-5.0	5.0	0.0	-5.0	20.0	10.0	-10.0
19	8.0	5.0	-3.0	2.0	1.0	-1.0	10.0	6.0	-4.0
20	10.0	8.0	-2.0	10.0	0.0	-10.0	20.0	8.0	-12.0
21	10.0	5.0	-5.0	5.0	2.0	-3.0	15.0	7.0	-8.0
22	9.0	5.0	-4.0	3.0	0.0	-3.0	12.0	5.0	-7.0
Mean	**12.0**	**7.5**	**-4.6**	**7.0**	**1.5**	**-5.5**	**19.0**	**9.0**	**-10.1**
Median	10.0	8.0	-5.0	5.0	1.0	-4.5	17.5	8.5	-9.0
Minimum	*5.0*	*2.0*	*-20.0*	*0.0*	*0.0*	*-17.0*	*10.0*	*4.0*	*-30.0*
Maximum	*30.0*	*10.0*	*0.0*	*20.0*	*6.0*	*0.0*	*40.0*	*16.0*	*0.0*
SEM	**1.2**	**0.5**	**1.0**	**1.0**	**0.4**	**0.9**	**1.7**	**0.7**	**1.4**
95% CI	**2.6**	**1.1**	**2.1**	**2.1**	**0.7**	**1.8**	**3.5**	**1.5**	**2.9**
	Δ%	**-38%**		**Δ%**	**-79%**		**Δ%**	**-53%**	
	p	**<0.0001**		**p**	**<0.0001**		**p**	**<0.0001**	
	Type of statistical test	Wilcoxon		**Type of statistical test**	t-test		**Type of statistical test**	t-test	
	% of subjects presenting improvement	**77%**		**% of subjects presenting improvement**	**91%**		**% of subjects presenting improvement**	**95%**	
	% of subjects without change	23%		**% of subjects without change**	9%		**% of subjects without change**	5%	
	% of subjects presenting worsening	0%		**% of subjects presenting worsening**	0%		**% of subjects presenting worsening**	0%	

	Papules			Pustules			Global inflammatory lesions		
Subject #	**D0**	**D28**	**ΔD28**	**D0**	**D28**	**ΔD28**	**D0**	**D28**	**ΔD28**
1	8.0	6.0	-2.0	2.0	3.0	1.0	10.0	9.0	-1.0
2	6.0	2.0	-4.0	2.0	0.0	-2.0	8.0	2.0	-6.0
3	10.0	5.0	-5.0	5.0	0.0	-5.0	15.0	5.0	-10.0
4	20.0	5.0	-15.0	5.0	0.0	-5.0	25.0	5.0	-20.0
5	7.0	2.0	-5.0	3.0	0.0	-3.0	10.0	2.0	-8.0
6	2.0	0.0	-2.0	8.0	0.0	-8.0	10.0	0.0	-10.0
7	5.0	2.0	-3.0	5.0	2.0	-3.0	10.0	4.0	-6.0
8	6.0	1.0	-5.0	4.0	0.0	-4.0	10.0	1.0	-9.0
9	5.0	3.0	-2.0	15.0	5.0	-10.0	20.0	8.0	-12.0
10	5.0	0.0	-5.0	1.0	0.0	-1.0	6.0	0.0	-6.0
11	3.0	3.0	0.0	3.0	0.0	-3.0	6.0	3.0	-3.0
12	3.0	2.0	-1.0	2.0	0.0	-2.0	5.0	2.0	-3.0
13	3.0	1.0	-2.0	7.0	1.0	-6.0	10.0	2.0	-8.0
14	5.0	0.0	-5.0	0.0	0.0	0.0	5.0	0.0	-5.0
15	4.0	3.0	-1.0	6.0	0.0	-6.0	10.0	3.0	-7.0
16	2.0	2.0	0.0	8.0	5.0	-3.0	10.0	7.0	-3.0
17	8.0	5.0	-3.0	2.0	0.0	-2.0	10.0	5.0	-5.0
18	8.0	5.0	-3.0	2.0	0.0	-2.0	10.0	5.0	-5.0
19	7.0	0.0	-7.0	3.0	0.0	-3.0	10.0	0.0	-10.0
20	5.0	2.0	-3.0	1.0	0.0	-1.0	6.0	2.0	-4.0
21	15.0	10.0	-5.0	5.0	1.0	-4.0	20.0	11.0	-9.0
22	3.0	0.0	-3.0	3.0	0.0	-3.0	6.0	0.0	-6.0
Mean	**6.4**	**2.7**	**-3.7**	**4.2**	**0.8**	**-3.4**	**10.5**	**3.5**	**-7.1**
Median	5.0	2.0	-3.0	3.0	0.0	-3.0	10.0	2.5	-6.0
Minimum	*2.0*	*0.0*	*-15.0*	*0.0*	*0.0*	*-10.0*	*5.0*	*0.0*	*-20.0*
Maximum	*20.0*	*10.0*	*0.0*	*15.0*	*5.0*	*1.0*	*25.0*	*11.0*	*-1.0*
SEM	**0.9**	**0.5**	**0.7**	**0.7**	**0.3**	**0.5**	**1.1**	**0.7**	**0.9**
95% CI	**1.9**	**1.1**	**1.4**	**1.5**	**0.7**	**1.1**	**2.3**	**1.4**	**1.8**
		Δ%	**-58%**		**Δ%**	**-82%**		**Δ%**	**-67%**
		p	**<0.0001**		**p**	**<0.0001**		**p**	**<0.0001**
		Type of statistical test	Wilcoxon		**Type of statistical test**	t-test		**Type of statistical test**	t-test
		% of subjects presenting improvement	**91%**		**% of subjects presenting improvement**	**91%**		**% of subjects presenting improvement**	**100%**
		% of subjects without change	9%		**% of subjects without change**	5%		**% of subjects without change**	0%
		% of subjects presenting worsening	0%		**% of subjects presenting worsening**	5%		**% of subjects presenting worsening**	0%

Subject #	Total lesions			Comedogenic/ Acnegenic reaction (yes/no)
	D0	D28	ΔD28	
1	40.0	22.0	-18.0	No
2	48.0	12.0	-36.0	No
3	35.0	15.0	-20.0	No
4	45.0	17.0	-28.0	No
5	30.0	6.0	-24.0	No
6	25.0	6.0	-19.0	No
7	25.0	13.0	-12.0	No
8	25.0	7.0	-18.0	No
9	50.0	23.0	-27.0	No
10	16.0	8.0	-8.0	No
11	16.0	13.0	-3.0	No
12	20.0	10.0	-10.0	No
13	25.0	8.0	-17.0	No
14	17.0	5.0	-12.0	No
15	30.0	16.0	-14.0	No
16	35.0	23.0	-12.0	No
17	40.0	15.0	-25.0	No
18	30.0	15.0	-15.0	No
19	20.0	6.0	-14.0	No
20	26.0	10.0	-16.0	No
21	35.0	18.0	-17.0	No
22	18.0	5.0	-13.0	No
Mean	**29.6**	**12.4**	**-17.2**	
Median	28.0	12.5	-16.5	
Minimum	*16.0*	*5.0*	*-36.0*	
Maximum	*50.0*	*23.0*	*-3.0*	
SEM	**2.2**	**1.2**	**1.6**	
95% CI	**4.6**	**2.6**	**3.3**	

Δ%	**-58%**
p	**<0.0001**
Type of statistical test	t-test
% of subjects presenting improvement	**100%**
% of subjects without change	0%
% of subjects presenting worsening	0%

7.5.2 Statistical analysis

STUDY : _21E1365

STATISTICAL ANALYSIS

25/04/2022

Statistical software:

SAS v9.4

Methodology:

For each statistical comparison, if the normality assumption was not rejected using a Shapiro-Wilk test (α=0.01), a paired t-test was performed. In case of normality rejection, a non-parametric approach was carried out using a Wilcoxon signed rank test.

The Statistical tests are two-tailed.

The type I error is set at α=0.05.

1. Statistical comparisons

Parameter	Product	Kinetic	Mean ± SEM	p-value	Statistically significant
Blackheads	**Product**	**D28-D0**	-4.6 ± 1.0	<0.0001*	Yes
Microcysts	**Product**	**D28-D0**	-5.5 ± 0.9	<0.0001°	Yes
Globalretention allesions	**Product**	**D28-D0**	-10.1 ± 1.4	<0.0001°	Yes
Papules	**Product**	**D28-D0**	-3.7 ± 0.7	<0.0001*	Yes
Pustules	**Product**	**D28-D0**	-3.4 ± 0.5	<0.0001°	Yes
Globalinflammatorylesions	**Product**	**D28-D0**	-7.1 ± 0.9	<0.0001°	Yes
Totallesions	**Product**	**D28-D0**	-17.2 ± 1.6	<0.0001°	Yes

°paired t-test
*Wilcoxon signed rank test
Note: p-value < 0.05 is statistically significant

2. Descriptive statistics

			D0	D28
Blackheads	**Product**	**N (miss)**	22 (0)	22 (0)
		mean (SD)	12.0 (5.8)	7.5 (2.6)
		median	10.0	8.0
		min ; max	5.0 ; 30.0	2.0 ; 10.0
Microcysts	**Product**	**N (miss)**	22 (0)	22 (0)
		mean (SD)	7.0 (4.7)	1.5 (1.7)
		median	5.0	1.0
		min ; max	0.0 ; 20.0	0.0 ; 6.0
Globalretention allesions	**Product**	**N (miss)**	22 (0)	22 (0)
		mean (SD)	19.0 (7.8)	9.0 (3.3)
		median	17.5	8.5
		min ; max	10.0 ; 40.0	4.0 ; 16.0
Papules	**Product**	**N (miss)**	22 (0)	22 (0)
		mean (SD)	6.4 (4.3)	2.7 (2.5)
		median	5.0	2.0
		min ; max	2.0 ; 20.0	0.0 ; 10.0
Pustules	**Product**	**N (miss)**	22 (0)	22 (0)
		mean (SD)	4.2 (3.3)	0.8 (1.6)
		median	3.0	0.0
		min ; max	0.0 ; 15.0	0.0 ; 5.0
Globalinflammatorylesions	**Product**	**N (miss)**	22 (0)	22 (0)
		mean (SD)	10.5 (5.2)	3.5 (3.1)
		median	10.0	2.5
		min ; max	5.0 ; 25.0	0.0 ; 11.0
Totallesions	**Product**	**N (miss)**	22 (0)	22 (0)
		mean (SD)	29.6 (10.3)	12.4 (5.8)
		median	28.0	12.5
		min ; max	16.0 ; 50.0	5.0 ; 23.0

3.Box-plot


Parameter = Blackheads
30
20
10
0
-10
-20
Value
D0
D28
D28-D0
Time
Product
Product


Parameter = Microcysts
20
10
0
-10
-20
Value
D0
D28
D28-D0
Time
Product
Product


Parameter = Globalretentionallesions
40
20
0
-20
Value
D0
D28
D28-D0
Time
Product
Product


Parameter = Papules
20
10
0
-10
Value
D0
D28
D28-D0
Time
Product
Product


Parameter = Pustules
15
10
5
0
-5
-10
Value
D0
D28
D28-D0
Time
Product
Product


Parameter = Globalinflammatorylesions
20
10
0
-10
-20
Value
D0
D28
D28-D0
Time
Product
Product



4.SAS output

The UNIVARIATE Procedure
Variable: value (Value)

Parameter=Blackheads Product=Product Time=D28-D0

Basic Statistical Measures			
Location		**Variability**	
Mean	-4.59091	**Std Deviation**	4.81722
Median	-5.00000	**Variance**	23.20563
Mode	-5.00000	**Range**	20.00000
		Interquartile Range	3.00000

Tests for Location: Mu0=0				
Test		**Statistic**		**p Value**
Student's t	**t**	-4.47006	**Pr > |t|**	0.0002
Sign	**M**	-8.5	**Pr >= |M|**	<.0001
Signed Rank	**S**	-76.5	**Pr >= |S|**	<.0001

Tests for Normality				
Test		**Statistic**		**p Value**
Shapiro-Wilk	**W**	0.75153	**Pr < W**	<0.0001
Kolmogorov-Smirnov	**D**	0.329798	**Pr > D**	<0.0100
Cramer-von Mises	**W-Sq**	0.329549	**Pr > W-Sq**	<0.0050
Anderson-Darling	**A-Sq**	1.883043	**Pr > A-Sq**	<0.0050

The UNIVARIATE Procedure
Variable: value (Value)

Parameter=Microcysts Product=Product Time=D28-D0

Basic Statistical Measures			
Location		**Variability**	
Mean	-5.50000	**Std Deviation**	4.06788
Median	-4.50000	**Variance**	16.54762
Mode	-4.00000	**Range**	17.00000
		Interquartile Range	5.00000

Tests for Location: Mu0=0				
Test		**Statistic**		**p Value**
Student's t	**t**	-6.34171	**Pr > |t|**	<.0001
Sign	**M**	-10	**Pr >= |M|**	<.0001
Signed Rank	**S**	-105	**Pr >= |S|**	<.0001

Tests for Normality				
Test		**Statistic**		**p Value**
Shapiro-Wilk	**W**	0.920051	**Pr < W**	0.0762
Kolmogorov-Smirnov	**D**	0.185276	**Pr > D**	0.0476
Cramer-von Mises	**W-Sq**	0.085339	**Pr > W-Sq**	0.1719
Anderson-Darling	**A-Sq**	0.534469	**Pr > A-Sq**	0.1564

The UNIVARIATE Procedure
Variable: value (Value)

Parameter=Globalretentionallesions Product=Product Time=D28-D0

Basic Statistical Measures			
Location		**Variability**	
Mean	-10.0909	**Std Deviation**	6.46536
Median	-9.0000	**Variance**	41.80087
Mode	-9.0000	**Range**	30.00000
		Interquartile Range	5.00000

Note: The mode displayed is the smallest of 2 modes with a count of 4.

Tests for Location: Mu0=0				
Test		**Statistic**		**p Value**
Student's t	**t**	-7.32064	**Pr > |t|**	<.0001
Sign	**M**	-10.5	**Pr >= |M|**	<.0001
Signed Rank	**S**	-115.5	**Pr >= |S|**	<.0001

Tests for Normality				
Test		Statistic		p Value
Shapiro-Wilk	W	0.879043	Pr < W	0.0116
Kolmogorov-Smirnov	D	0.232882	Pr > D	<0.0100
Cramer-von Mises	W-Sq	0.194762	Pr > W-Sq	0.0054
Anderson-Darling	A-Sq	1.010234	Pr > A-Sq	0.0094

The UNIVARIATE Procedure
Variable: value (Value)

Parameter=Papules Product=Product Time=D28-D0

Basic Statistical Measures			
Location		Variability	
Mean	-3.68182	Std Deviation	3.12267
Median	-3.00000	Variance	9.75108
Mode	-5.00000	Range	15.00000
		Interquartile Range	3.00000

Tests for Location: Mu0=0				
Test		Statistic		p Value
Student's t	t	-5.53028	Pr > |t|	<.0001
Sign	M	-10	Pr >= |M|	<.0001
Signed Rank	S	-105	Pr >= |S|	<.0001

Tests for Normality				
Test		Statistic		p Value
Shapiro-Wilk	W	0.777111	Pr < W	0.0002
Kolmogorov-Smirnov	D	0.245555	Pr > D	<0.0100
Cramer-von Mises	W-Sq	0.196216	Pr > W-Sq	0.0051
Anderson-Darling	A-Sq	1.29999	Pr > A-Sq	<0.0050

The UNIVARIATE Procedure
Variable: value (Value)

Parameter=Pustules Product=Product Time=D28-D0

Basic Statistical Measures			
Location		Variability	
Mean	-3.40909	Std Deviation	2.53845
Median	-3.00000	Variance	6.44372
Mode	-3.00000	Range	11.00000
		Interquartile Range	3.00000

Tests for Location: Mu0=0				
Test		Statistic		p Value
Student's t	t	-6.29914	Pr > |t|	<.0001
Sign	M	-9.5	Pr >= |M|	<.0001
Signed Rank	S	-113.5	Pr >= |S|	<.0001

Tests for Normality				
Test		Statistic		p Value
Shapiro-Wilk	W	0.94315	Pr < W	0.2297
Kolmogorov-Smirnov	D	0.200379	Pr > D	0.0214
Cramer-von Mises	W-Sq	0.104394	Pr > W-Sq	0.0937
Anderson-Darling	A-Sq	0.556411	Pr > A-Sq	0.1379

The UNIVARIATE Procedure
Variable: value (Value)

Parameter=Globalinflammatorylesions Product=Product Time=D28-D0

Basic Statistical Measures			
Location		Variability	
Mean	-7.09091	Std Deviation	4.02266
Median	-6.00000	Variance	16.18182
Mode	-6.00000	Range	19.00000
		Interquartile Range	4.00000

Tests for Location: Mu0=0				
Test		Statistic		p Value
Student's t	t	-8.26798	Pr > |t|	<.0001
Sign	M	-11	Pr >= |M|	<.0001
Signed Rank	S	-126.5	Pr >= |S|	<.0001

Tests for Normality				
Test		Statistic		p Value
Shapiro-Wilk	W	0.888394	Pr < W	0.0175
Kolmogorov-Smirnov	D	0.152332	Pr > D	>0.1500
Cramer-von Mises	W-Sq	0.08479	Pr > W-Sq	0.1752
Anderson-Darling	A-Sq	0.634347	Pr > A-Sq	0.0885

The UNIVARIATE Procedure
Variable: value (Value)

Parameter=Totallesions Product=Product Time=D28-D0

Basic Statistical Measures			
Location		Variability	
Mean	-17.1818	**Std Deviation**	7.39779
Median	-16.5000	**Variance**	54.72727
Mode	-12.0000	**Range**	33.00000
		Interquartile Range	8.00000

Tests for Location: Mu0=0				
Test		Statistic		p Value
Student's t	**t**	-10.8938	**Pr > |t|**	<.0001
Sign	**M**	-11	**Pr >= |M|**	<.0001
Signed Rank	**S**	-126.5	**Pr >= |S|**	<.0001

Tests for Normality				
Test		Statistic		p Value
Shapiro-Wilk	**W**	0.961931	**Pr < W**	0.5293
Kolmogorov-Smirnov	**D**	0.137786	**Pr > D**	>0.1500
Cramer-von Mises	**W-Sq**	0.071986	**Pr > W-Sq**	>0.2500
Anderson-Darling	**A-Sq**	0.402356	**Pr > A-Sq**	>0.2500

7.6 SUBJECTIVE EVALUATION QUESTIONNAIRE

AFTER 28 DAYS OF USE

GENERAL APPRECIATION OF THE PRODUCT AND ITS PROPERTIES

	What did you think about this product?	very pleasant	pleasant	neither pleasant nor unpleasant	unpleasant	very unpleasant
1	What is you global appreciation of the product?	32%	45%	23%	0%	0%
		agree	**somewhat agree**	**neither agree nor disagree**	**somewhat disagree**	**disagree**
2	Is the use of product easy?	86%	14%	0%	0%	0%
3	Did you find this product pleasant to use?	59%	27%	9%	5%	0%

PRODUCT'S EFFICACY

	What did you think about the product's efficacy after 28 days of use?	agree	somewhat agree	neither agree nor disagree	somewhat disagree	disagree
6	The skin is soft	9%	64%	14%	14%	0%
7	The skin is healthy looking	27%	41%	27%	5%	0%
8	The skin is purified	50%	36%	5%	9%	0%
9	The product does not dry out the skin	14%	32%	36%	5%	14%
10	The product is suitable for dry skin (if applicable) (n=15)	13%	27%	33%	7%	20%
11	The product is suitable for sensitive skin (if applicable) (n=19)	16%	26%	37%	21%	0%
12	The product reduces pimples and imperfections	50%	27%	14%	9%	0%
13	The product is easy to rinse	77%	18%	5%	0%	0%
14	The product foams well	64%	23%	5%	9%	0%
15	The product leaves the skin comfortable	32%	32%	23%	14%	0%
16	The product is suitable for my skin type	32%	41%	14%	9%	5%

ACCEPTABILITY

		yes	no
17	During this study did you feel any cutaneous irritation sensation?	68%	32%
18	During this study did you notice any unusual appearance of spots and/or blackheads?	0%	100%

FUTURE USE OF THE PRODUCT

		yes	no
19	Would you like to continue to use the product?	82%	18%
20	At the end of this study would you like to buy this product (regardless of the price)?	77%	23%

8 APPENDICES - ETHICAL REQUIREMENTS AND REGULATORY STANDARDS

8.1 ADVERSE EVENT

8.1.1 Adverse Event (AE)

Any noxious symptom, occurring in a subject taking part in a clinical trial, whether or not this symptom is related to the study or the study product(s) (e.g. flu, headache, abnormal biological analysis…).

8.1.2 Undesirable Effect (UE) / Adverse Reaction (AR)

For a cosmetic product, an **undesirable effect** is defined as an adverse reaction for human health attributable to the normal or reasonably foreseeable use of the cosmetic product(s).
There are 5 levels of imputability: very likely, likely, not clearly attributable, unlikely and excluded (ANSM methodology).

The severity/intensity of undesirable effects/adverse events can be graded on a three-point scale:
- **mild**: discomfort noted, that does not disturb normal daily activities;
- **moderate**: discomfort sufficient to reduce or affect normal daily activities;
- **severe**: inability to work or have normal daily activities.

8.1.3 Serious Adverse Event (SAE) / Serious Undesirable Effect (SUE)

Any event that:
- results in death (note: death is the outcome, not the event);
- is life threatening;
- requires in-patient hospitalization (at least one night) or prolongation of existing hospitalization (does not include hospitalization scheduled before the inclusion);
- results in temporary or permanent functional incapacity or disability;
- is a congenital anomaly;
- is considered like by the investigator.

8.1.4 Documentation

All concomitant treatments are reported in the CRF (Case Report Form); only those started after the beginning of the study are reported in the study report.

All Undesirable Effects are reported in the CRF and the study report.
If it requires the temporary or definitive termination of the study product, the need for a corrective treatment or the withdrawal of the subject, an Adverse Event form is completed.

All SAE/SUE are reported in the CRF and the study report.

8.1.5 Notification

The investigator declares to the Sponsor, by e-mail, the occurrence of adverse reactions according to their severity and their unexpectedness (according to the investigator's advice).

All SAE/SUE are transmitted by e-mail to the Sponsor without delay, at the latest 24 hours after knowledge of their occurrence.
A SAE/SUE declaration form signed by a physician is sent, within 48 hours, by e-mail with acknowledgement of receipt.

8.1.6 Follow-up

When an adverse event linked to the investigational product or the protocol persists at the end of the study, the Investigator ensures that the subject is followed up until total resolution of the event or stabilization of the symptoms without releasing the Sponsor of any obligation or responsibility.

8.1.7 Occurrence of pregnancy

The occurrence of a pregnancy (reported or diagnosed) after inclusion in the study is considered as an intercurrent event not related to the study product(s) nor the protocol and induces the immediate dropping out of the subject.
Any pregnancy that occurs during the study period is reported by e-mail to the Sponsor within 24 hours following its discovering.
A follow-up is done according to the current internal procedures until the completion/termination of the pregnancy or its interruption.

8.2 PREMATURE TERMINATION OF SUBJECT PARTICIPATION

In compliance with the Helsinki Declaration (1964) and its successive updates, subjects have the right to exit from the study at any time and for any motive.

The investigator can also interrupt the subject participation in the study prematurely in the case of a disease occurrence, a pregnancy or the occurrence of an adverse reaction.

The Sponsor can demand that any subject be excluded from the study for major infringements to the protocol, for administrative reasons or any other motive however this would need to be clearly documented with a rationale as to why.

Nevertheless, premature removal of a high percentage of subjects from the study can make it difficult or impossible to interpret. Consequently, any premature exit without valid motives should be avoided as much as possible and is carefully documented in the case report form, the final report and, if necessary, in the Adverse Event form.

Every premature exit must be classified under one of the following headings:

- presence of a non-inclusion criteria;
- Undesirable Effect / Adverse Event occurrence;
- Serious Adverse Event / Serious Adverse Effect occurrence;
- withdrawal of consent;
- lost to follow-up;
- appearance of non-inclusion criteria;
- non-adherence to the protocol;
- other reason.

No replacement is foreseen as 10% additional subjects are planned to be included in the study.

8.3 CONFIDENTIALITY AND GENERAL DATA PROTECTION REGULATION

In this study, EUROFINS Dermscan/Pharmascan processes personal data of subjects on behalf of the Sponsor, in accordance with the rules on the protection of personal data and, in particular, the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data. For this purpose, EUROFINS Dermscan/Pharmascan limits the collection and use of personal data to that which is needed for analysis and control purposes, by ensuring their security and integrity and by guaranteeing their confidentiality.

EUROFINS Dermscan/Pharmascan makes sure beforehand and throughout the duration of the data-processing:
- of the compliance with the obligations of the applicable data protection law,
- to inform subjects of their personal data-processing after obtaining their consent,
- to implement and maintain appropriate technical and organisational measures.

An identification code is attributed to each subject for the purpose to keep his/her identity confidential. This code consists of the first two letters/first letter of the subject's name and the first letter of his/her first name.

According to Article 14 of GDPR, the concerned subject must be informed of the identity and the contact details of the Controller and, where applicable, of the controller's representative. However, considering the objective of the study, to avoid any bias in the investigational product evaluation, the identity of the Sponsor is not revealed to the subject participating.

8.4 DATA COLLECTION AND VALIDATION

The personnel in charge of the study collects data into individual case report forms in electronic (e-CRF CleanWEB™ internet platform) or paper format and/or directly from measurement software.
When information is collected in paper format, the simple/double data entry is then done from these supports by the designed operator(s), without any interpretation, in specific MS EXCEL databases.
The Project Manager or assistant checks the double data entry by comparing both databases.

Then the coherence of the whole data set is checked as well as formulas used in the EXCEL tables (calculation formulas, selected data…).
When all the controls are done, the database is locked.

8.5 QUALITY MANAGEMENT

In order to ensure that the clinical trials are in compliance with the Sponsor's requirement, EUROFINS Dermscan/Pharmascan has implemented a quality management system which has been certified ISO 9001: 2015.
This quality assurance system includes appropriate Good Clinical Practices (GCP) and regulation requirements.

Each study report is subjected to a quality inspection by a member of the EUROFINS Dermscan/Pharmascan Proofreading Committee. The proofreader is chosen because he(she) is not involved in the audited study. The inspection of the study report allows to confirm that the results reflect exactly the study raw data and that the study fulfils any standard and regulatory requirements.
A certificate of quality inspection signed by the person who checked the report is enclosed in each study.

8.6 ARCHIVES OF STUDY DOCUMENTS

<table>
<tr><td>STUDY DOCUMENTS AND DATA</td><td colspan="2">TIME AFTER DISPATCH OF THE FINAL REPORT:
 

0 1 (maximum) 10 YEARS</td><td></td></tr>
<tr><td>Paper</td><td>Stored at the investigation center</td><td>Securely archived at an approved service provider</td><td rowspan="2">Destruction of the archives unless otherwise stipulated in writing by the Sponsor</td></tr>
<tr><td>Digital</td><td colspan="2">Securely archived</td></tr>
</table>